These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 402691)

  • 61. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relationship between 4a and 4b HLA-determined specificities and C3 receptors of leukocyte membrane.
    Ferreira A; Fotino M; Nussenzweig V
    Eur J Immunol; 1976 Nov; 6(11):832-3. PubMed ID: 1087238
    [No Abstract]   [Full Text] [Related]  

  • 64. In vitro complement activation by rabbit lymphocytes and thymocytes in autologous serum.
    Wilson AB; Lachmann PJ; Coombs RR
    Immunology; 1979 May; 37(1):25-34. PubMed ID: 112041
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
    Robertson J; Caldwell JR; Castle JR; Waldman RH
    J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.
    Ramos OF; Sármay G; Klein E; Yefenof E; Gergely J
    Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5470-4. PubMed ID: 3895232
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
    Berger M; Fleisher TA
    J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Properdin: New roles in pattern recognition and target clearance.
    Kemper C; Hourcade DE
    Mol Immunol; 2008 Oct; 45(16):4048-56. PubMed ID: 18692243
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modulation of the alternative complement pathways by beta 1 H globulin.
    Whaley K; Ruddy S
    J Exp Med; 1976 Nov; 144(5):1147-63. PubMed ID: 62817
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pneumococcal type-associated variability in alternate complement pathway activation.
    Fine DP
    Infect Immun; 1975 Oct; 12(4):772-8. PubMed ID: 329
    [TBL] [Abstract][Full Text] [Related]  

  • 72. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
    Praz F; Lesavre P
    J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Structure and function of a family of tick-derived complement inhibitors targeting properdin.
    Braunger K; Ahn J; Jore MM; Johnson S; Tang TTL; Pedersen DV; Andersen GR; Lea SM
    Nat Commun; 2022 Jan; 13(1):317. PubMed ID: 35031611
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Receptors for C3 on rat peritoneal mast cells.
    Sher A; McIntyre SL
    J Immunol; 1977 Aug; 119(2):722-5. PubMed ID: 407303
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody.
    Patrick Sissons JG; Schreiber RD; Perrin LH; Cooper NR; Müller-Eberhard HJ; Oldstone MB
    J Exp Med; 1979 Sep; 150(3):445-54. PubMed ID: 479760
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A recombinant two-module form of human properdin is an inhibitor of the complement alternative pathway.
    Kouser L; Abdul-Aziz M; Tsolaki AG; Singhal D; Schwaeble WJ; Urban BC; Khan HA; Sim RB; Kishore U
    Mol Immunol; 2016 May; 73():76-87. PubMed ID: 27060503
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Receptor for the fourth component of complement on human B lymphocytes and cultured human lymphoblastoid cells.
    Bokisch VA; Sobel AT
    J Exp Med; 1974 Nov; 140(5):1336-47. PubMed ID: 4547573
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
    Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
    J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.